Moreover, in preclinical models of JAK2/IDH-mutant MPNs, the combination of JAK2 and IDH inhibitors showed a strong inhibition of tumor growth and suppression of abnormal 2-hydroxyglutarate production [193]. The gene discussed is JAK2; the disease is neoplasm.